vimarsana.com
Home
Live Updates
REGENXBIO Reports Fourth Quarter 2022 and Full-Year 2022 Fin
REGENXBIO Reports Fourth Quarter 2022 and Full-Year 2022 Fin
REGENXBIO Reports Fourth Quarter 2022 and Full-Year 2022 Financial Results and Recent Operational Highlights
Continued progress on '5x'25' strategy to advance five AAV Therapeutics from REGENXBIO's internal pipeline and licensed programs into pivotal-stage or...
Related Keywords
Brazil ,
Rockville ,
Maryland ,
United States ,
United Kingdom ,
Dana Cormack ,
Chris Brinzey ,
Ultragenyx Pharmaceutical Inc ,
Technology Platform ,
Technology Platform Licensees ,
Rocket Pharmaceuticals Inc ,
Nasdaq ,
United Kingdom Health Authority ,
Technology Licensee Program ,
Development Expenses ,
Exchange Commission ,
Corporate Communications ,
Securities Exchange ,
Manufacturing Innovation Center ,
Chief Executive Officer ,
Hunter Syndrome ,
Innovation Center ,
Biologics License Application ,
Long Term Follow Up ,
Duchenne Muscular Dystrophy ,
Mucopolysaccharidosis Type ,
Licensee Program Highlights ,
Rocket Pharmaceuticals ,
Ultragenyx Pharmaceutical ,
Ornithine Transcarbamylase ,
Administrative Expenses ,
Platform Licensees ,
Securities Act ,
Securities Exchange Act ,
Financial Condition ,
Tax Benefit ,
Comprehensive Income ,
Regenxbio Inc ,